TMIC-50. SIGLEC-15 IS A NEW MYELOID CHECKPOINT IN GBM, WHOSE SUPPRESSION LEADS TO EXTREMELY DURABLE RESPONSES WITH ONCOLYTIC THERAPY

作者
Ashwani Kesarwani,Amanda De Andrade Costa,Tong Hu,Jeremy N. Rich,Albert Kim,Pei‐Yong Shi,Michael S. Diamond,Milan G. Chheda
出处
期刊:Neuro-oncology [Oxford University Press]
卷期号:25 (Supplement_5): v289-v289
标识
DOI:10.1093/neuonc/noad179.1116
摘要

Abstract Zika virus (ZIKV) significantly increases survival in multiple syngeneic glioma mouse models; like other oncolytic therapies, it generates a potent, anti-tumor CD8+ T-cell response. Post-ZIKV, we observe a 32-fold increase in myeloid cells in the tumor microenvironment. Siglec-15 is a newly identified myeloid immune checkpoint in cancer, which suppresses T-cell activation; an antibody targeting Siglec-15 is currently in clinical trial for lung cancer. Using immunostaining, for the first time, we report Siglec-15 is expressed on myeloid cells in human GBM specimens. In syngeneic murine models, anti-Siglec-15 alone does not improve survival. However, in combination with ZIKV, anti-Siglec-15 significantly improves survival in the CT2A, SB28, and GL261 models. For example, in the CT2A model, the combination increased long-term survivors (at least 90 days) to 60%, compared to 20% with ZIKV alone and 0% with no treatment. To further confirm the role of Siglec-15, we used Siglec-15 knockout (KO) mice and observed 70% long-term survivor rate in Siglec-15 KO mice treated with ZIKV, compared to 40% in wild-type mice (B/6) with ZIKV. ZIKV treatment in Siglec-15 KO mice led to activation of CD8 T-cells and increased expression of cytotoxic molecules granzyme B and perforin, indicating enhanced anti-tumor activity. Additionally, we detected high levels IFN-gamma and TNF-alpha, further supporting the anti-tumor response. We further improved efficacy by targeting PD-1. This combination resulted in 90% long-term survivors. Moreover, in a model for recurrence, upon contralateral rechallenge with CT2A in long-term survivors, we observed long-term memory T-cell responses, with increased numbers of CD8+ T-cells displaying effector and resident memory cell phenotypes, compared to age-matched controls. We obtained similar results with immune-resistant SB28 model. This work suggests that oncolytic therapy combined with blocking myeloid checkpoint Siglec-15, using an agent already in humans, and blocking CD8+ T cell checkpoint with anti-PD1, is worthy of study in humans.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
大个的应助被彪壮的绮烟采纳,获得10
1秒前
涨誊完成签到,获得积分20
3秒前
AN发布了新的文献求助10
4秒前
阿申爱乐的应助被dalong采纳,获得40
4秒前
深情安青的应助被三分之二采纳,获得10
5秒前
yunlong完成签到 ,获得积分10
6秒前
6秒前
6秒前
西陆发布了新的文献求助10
7秒前
WilliamTT发布了新的文献求助10
7秒前
东方天奇完成签到 ,获得积分10
7秒前
8秒前
syvshc的应助被RuYi采纳,获得10
8秒前
9秒前
慕青的应助被阿耒采纳,获得10
9秒前
9秒前
SchoLar完成签到 ,获得积分10
9秒前
慕青的应助被脑子大聪明采纳,获得10
9秒前
10秒前
10秒前
10秒前
11秒前
TCA关注了科研通微信公众号
11秒前
11秒前
科研通AI65的应助被小白采纳,获得10
11秒前
寻找布冯发布了新的文献求助10
12秒前
1111111完成签到,获得积分10
12秒前
12秒前
12秒前
lele发布了新的文献求助10
12秒前
fantasy的应助被和道一文字采纳,获得10
13秒前
动听千山发布了新的文献求助10
13秒前
玉米侠发布了新的文献求助10
14秒前
星燃发布了新的文献求助10
14秒前
Cuzz关注了科研通微信公众号
15秒前
15秒前
拼搏可冥发布了新的文献求助10
16秒前
Artsy发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177767
求助须知:如何正确求助?哪些是违规求助? 9568590
关于积分的说明 21799821
捐赠科研通 7772374
什么是DOI,文献DOI怎么找? 3432476
关于科研通互助平台的介绍 2556695
邀请新用户注册赠送积分活动 2478034